Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Interest & Investment Income (2023 - 2025)

Historic Interest & Investment Income for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2025 value amounting to -$515000.0.

  • Orchestra BioMed Holdings' Interest & Investment Income fell 15622.27% to -$515000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $137000.0, marking a year-over-year decrease of 9652.46%. This contributed to the annual value of $3.4 million for FY2024, which is 1280.85% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Interest & Investment Income stood at -$515000.0 for Q3 2025, which was down 15622.27% from -$36000.0 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Interest & Investment Income registered a high of $1.1 million during Q4 2023, and its lowest value of -$515000.0 during Q3 2025.
  • Moreover, its 3-year median value for Interest & Investment Income was $902000.0 (2024), whereas its average is $554888.9.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first grew by 10.93% in 2024, then tumbled by 15622.27% in 2025.
  • Orchestra BioMed Holdings' Interest & Investment Income (Quarter) stood at $1.1 million in 2023, then tumbled by 52.89% to $522000.0 in 2024, then plummeted by 198.66% to -$515000.0 in 2025.
  • Its Interest & Investment Income stands at -$515000.0 for Q3 2025, versus -$36000.0 for Q2 2025 and $166000.0 for Q1 2025.